{"id":"citalopram-celexa","safety":{"commonSideEffects":[{"rate":"15-21%","effect":"Nausea"},{"rate":"10-18%","effect":"Somnolence"},{"rate":"9-20%","effect":"Dry mouth"},{"rate":"8-14%","effect":"Sweating"},{"rate":"8-13%","effect":"Tremor"},{"rate":"8-15%","effect":"Diarrhea"},{"rate":"10-15%","effect":"Insomnia"},{"rate":"10-15%","effect":"Sexual dysfunction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Citalopram is a selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter protein, preventing the reabsorption of serotonin from the synaptic cleft back into presynaptic neurons. This increases serotonin concentration in the extracellular space, enhancing serotonergic neurotransmission. This mechanism is thought to improve mood and reduce anxiety symptoms in depression and related disorders.","oneSentence":"Citalopram selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:30.730Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Panic disorder"}]},"trialDetails":[{"nctId":"NCT07488910","phase":"PHASE4","title":"Dynamic Networks in Depression Treatment: Mechanisms of Change in Pharmacological, Psychological and Combined Treatment of Depression","status":"NOT_YET_RECRUITING","sponsor":"Goethe University","startDate":"2026-02","conditions":"Depression - Major Depressive Disorder","enrollment":90},{"nctId":"NCT07478796","phase":"PHASE4","title":"TDM-Guided Treatment With SSRIs in Hospitalized Adults and Children","status":"RECRUITING","sponsor":"Poznan University of Medical Sciences","startDate":"2025-04-03","conditions":"Depression - Major Depressive Disorder, Depressive Episodes","enrollment":180},{"nctId":"NCT07480525","phase":"NA","title":"Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2026-03-20","conditions":"Depression - Major Depressive Disorder","enrollment":200},{"nctId":"NCT04497168","phase":"PHASE2","title":"Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2021-04-01","conditions":"Parkinson Disease","enrollment":58},{"nctId":"NCT05901571","phase":"NA","title":"Acupuncture and Escitalopram for Treating Major Depression Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Shanghai 7th People's Hospital","startDate":"2026-11","conditions":"Depressive Disorder, Major","enrollment":216},{"nctId":"NCT07139834","phase":"PHASE1","title":"Pattern Separation in Major Depressive Disorder","status":"NOT_YET_RECRUITING","sponsor":"Jeffrey Miller","startDate":"2026-04","conditions":"Major Depressive Disorder (MDD)","enrollment":30},{"nctId":"NCT05017311","phase":"PHASE4","title":"Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)","status":"RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2023-01-20","conditions":"Major Depressive Disorder","enrollment":400},{"nctId":"NCT07432815","phase":"PHASE4","title":"Treatment of Psoriasis With Depression and/or Anxiety With Methotrexate vs Combined Methotrexate and Antidepressant","status":"COMPLETED","sponsor":"Cairo University","startDate":"2025-02-01","conditions":"Depression, Anxiety, Psoriasis","enrollment":40},{"nctId":"NCT06049797","phase":"","title":"A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2023-11-15","conditions":"Hot Flashes","enrollment":999},{"nctId":"NCT06826326","phase":"PHASE2","title":"Neuroimaging of Escitalopram in Autism Spectrum Disorder","status":"ENROLLING_BY_INVITATION","sponsor":"Kathryn Unruh","startDate":"2025-04-28","conditions":"Autism Spectrum Disorder","enrollment":5},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","enrollment":1600},{"nctId":"NCT07399795","phase":"","title":"Citalopram and the Risk of Serious Adverse Events","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2008-01-01","conditions":"Chronic Kidney Disease (CKD), Elderly, Outpatient","enrollment":7110},{"nctId":"NCT07047651","phase":"PHASE4","title":"Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.","status":"RECRUITING","sponsor":"Dr. Stavroula Rakitzi","startDate":"2025-06-04","conditions":"Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder","enrollment":40},{"nctId":"NCT07274241","phase":"","title":"Escitalopram and the Risk of Serious Adverse Events","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2008-01-01","conditions":"Chronic Kidney Disease (CKD), Elderly, Outpatient","enrollment":12145},{"nctId":"NCT06216535","phase":"PHASE2","title":"Escitalopram in Asthma Patients With Frequent Exacerbation","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-05-19","conditions":"Asthma","enrollment":105},{"nctId":"NCT06937476","phase":"NA","title":"Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole","status":"RECRUITING","sponsor":"Central South University","startDate":"2025-05-08","conditions":"Major Depressive Disorder (MDD), Rumination","enrollment":108},{"nctId":"NCT05603104","phase":"PHASE3","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-04-27","conditions":"Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression","enrollment":1254},{"nctId":"NCT04747314","phase":"PHASE2, PHASE3","title":"Treating Negative Affect in Low Back Pain Patients","status":"COMPLETED","sponsor":"Ajay Wasan, MD, Msc","startDate":"2021-03-31","conditions":"Chronic Low Back Pain, Negative Affectivity","enrollment":308},{"nctId":"NCT05528224","phase":"NA","title":"Effect of SC-ICBT for Adults With OCD：A Three-Arm Randomized Controlled Trial","status":"TERMINATED","sponsor":"Shanghai Mental Health Center","startDate":"2022-09-01","conditions":"Obsessive-Compulsive Disorder","enrollment":46},{"nctId":"NCT06705478","phase":"PHASE2","title":"Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-02-15","conditions":"Major Depressive Disorder, Mild Neurocognitive Disorder, HIV","enrollment":186},{"nctId":"NCT07331987","phase":"NA","title":"Efficacy and Safety of Probiotics for Anxiety Depression","status":"NOT_YET_RECRUITING","sponsor":"Moon (Guangzhou) Biotechnology Co., Ltd.","startDate":"2026-03-01","conditions":"Anxiety Depression","enrollment":60},{"nctId":"NCT07328373","phase":"","title":"Neurobiological and Genomic Predictors of Relapse in Depression","status":"RECRUITING","sponsor":"Mehmet Kemal Arikan","startDate":"2025-01-01","conditions":"Healthy, Major Depressive Disorder (MDD)","enrollment":204},{"nctId":"NCT06965569","phase":"PHASE1","title":"Multiple Ascending Dose Phase 1 Study of ALA-3000","status":"COMPLETED","sponsor":"Alar Pharmaceuticals Inc.","startDate":"2025-04-21","conditions":"Treatment Resistant Depression","enrollment":37},{"nctId":"NCT00308893","phase":"PHASE4","title":"BDNF Gene Polymorphism and Antidepressants Treatment","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2006-07","conditions":"Depression","enrollment":188},{"nctId":"NCT07259525","phase":"","title":"Escitalopram Plasma Concentrations in Premenopausal and Postmenopausal Women","status":"NOT_YET_RECRUITING","sponsor":"Eskisehir Osmangazi University","startDate":"2026-01","conditions":"Therapeutic Drug Monitoring (TDM), Menopause, Depression - Major Depressive Disorder","enrollment":94},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT05289830","phase":"PHASE2","title":"Escitalopram to Placebo in Patients With Localized Pancreatic Cancer","status":"TERMINATED","sponsor":"Case Comprehensive Cancer Center","startDate":"2022-08-05","conditions":"Pancreatic Ductal Adenocarcinoma, Periampullary Cancer","enrollment":4},{"nctId":"NCT06692361","phase":"NA","title":"Assessment of the Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Patients With Major Depressive Disorder","status":"RECRUITING","sponsor":"Gang Wang","startDate":"2025-01-01","conditions":"Major Depressive Disorder (MDD), Depression - Major Depressive Disorder","enrollment":214},{"nctId":"NCT05944926","phase":"PHASE3","title":"Improving Outcomes in Depression in Primary Care in a Low Resource Setting","status":"RECRUITING","sponsor":"Harvard Medical School (HMS and HSDM)","startDate":"2024-03-18","conditions":"Depression, Depressive Disorder","enrollment":1500},{"nctId":"NCT05519683","phase":"PHASE2, PHASE3","title":"Home Transcutaneous Electrical Acustimulation (TEA)","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2022-11-02","conditions":"Irritable Bowel Syndrome With Constipation","enrollment":160},{"nctId":"NCT06500624","phase":"NA","title":"Comparative Efficacy of Escitalopram Monotherapy and Escitalopram in Adjuvant With Pizotifen in Depressive Disorder","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2024-06-03","conditions":"Depression","enrollment":88},{"nctId":"NCT05973786","phase":"PHASE3","title":"The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-02-11","conditions":"Bipolar Depression","enrollment":418},{"nctId":"NCT00285935","phase":"NA","title":"Cellular Aging and Neurobiology of Depression Study","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-12-16","conditions":"Major Depressive Disorder","enrollment":228},{"nctId":"NCT03843463","phase":"PHASE2","title":"Escitalopram and Language Intervention for Subacute Aphasia","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2021-07-18","conditions":"Aphasia, Stroke","enrollment":88},{"nctId":"NCT04846829","phase":"EARLY_PHASE1","title":"Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2017-04-24","conditions":"Major Depressive Disorder","enrollment":30},{"nctId":"NCT06591091","phase":"PHASE2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-09","conditions":"Depression","enrollment":80},{"nctId":"NCT06746441","phase":"PHASE2","title":"Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2024-12-01","conditions":"Major Depressive Disorder","enrollment":60},{"nctId":"NCT06001021","phase":"NA","title":"Cognitive Behavioral Couple Therapy for Perinatal Distress","status":"COMPLETED","sponsor":"Sameera Shafiq","startDate":"2023-08-15","conditions":"Perinatal Depression, Perinatal Anxiety","enrollment":96},{"nctId":"NCT07120880","phase":"PHASE3","title":"Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-09","conditions":"Major Depressive Disorder (MDD) With Insomnia","enrollment":184},{"nctId":"NCT07113145","phase":"PHASE4","title":"Comparative Evaluation of Safety and Efficacy of Dapoxetine, Silodosin, and Citalopram in the Management of Premature Ejaculation","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-06-01","conditions":"Premature (Early) Ejaculation","enrollment":450},{"nctId":"NCT03527043","phase":"PHASE2","title":"Impact of Escitalopram on Sperm DNA Fragmentation","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2017-10-01","conditions":"Sperm DNA Fragmentation, Infertility, Male","enrollment":75},{"nctId":"NCT06192589","phase":"PHASE1","title":"Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2024-02-08","conditions":"Cannabidiol, Drug Induced Liver Injury, Drug Interaction","enrollment":241},{"nctId":"NCT07077291","phase":"NA","title":"MBCT and Escitalopram for Treatment-Resistant Depression in Older Adults","status":"COMPLETED","sponsor":"Yun Zhang","startDate":"2020-02-01","conditions":"Treatment-resistant Depression (TRD)","enrollment":230},{"nctId":"NCT07074652","phase":"NA","title":"The Effect of SSRIs on Threat of Shock Potentiated Neural Circuitry","status":"COMPLETED","sponsor":"UCLH/UCL Joint Research Office","startDate":"2017-12-01","conditions":"Anxiety","enrollment":145},{"nctId":"NCT06949644","phase":"NA","title":"Pupillometry in Delayed Sleep Wake Phase Disorder","status":"NOT_YET_RECRUITING","sponsor":"Northwestern University","startDate":"2025-08-01","conditions":"Delayed Sleep-Wake Phase Disorder","enrollment":220},{"nctId":"NCT04344678","phase":"NA","title":"The Phosphodiesterase 5 Inhibitor Sildenafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2020-01-01","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT04410341","phase":"PHASE1, PHASE2","title":"The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2020-05-01","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT05830279","phase":"","title":"Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer","status":"RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2023-05-01","conditions":"Nausea With Vomiting Chemotherapy-Induced, Depression, Reactive, Cancer Pain","enrollment":600},{"nctId":"NCT03222570","phase":"PHASE2","title":"An Adaptive Algorithm-Based Approach to Treatment for Adolescent Depression","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2018-02-26","conditions":"Depressive Disorder","enrollment":90},{"nctId":"NCT03728673","phase":"PHASE2","title":"A Study Utilizing Escitalopram in Glioma Patients","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2019-03-06","conditions":"Glioma of Brain, Glioma","enrollment":20},{"nctId":"NCT03887624","phase":"EARLY_PHASE1","title":"Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-05-21","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":16},{"nctId":"NCT07025590","phase":"NA","title":"Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study)","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-04-22","conditions":"Cardiovascular Diseases (CVD), Depression Anxiety Disorder","enrollment":106},{"nctId":"NCT06476509","phase":"PHASE1","title":"A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET","status":"COMPLETED","sponsor":"Vigonvita Life Sciences","startDate":"2024-05-30","conditions":"Major Depressive Disorder","enrollment":20},{"nctId":"NCT05004987","phase":"PHASE4","title":"Aβ Dynamics in LLMD","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-02-04","conditions":"Alzheimer Disease, Major Depressive Disorder","enrollment":60},{"nctId":"NCT06210321","phase":"NA","title":"Pharmacogenetic Testing at Community Pharmacy","status":"NOT_YET_RECRUITING","sponsor":"Chantal Csajka","startDate":"2025-08-15","conditions":"Pharmacogenetic Testing","enrollment":270},{"nctId":"NCT05536414","phase":"PHASE2","title":"Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-09-12","conditions":"Major Depressive Disorder","enrollment":337},{"nctId":"NCT05470465","phase":"PHASE1","title":"Effect of Selective Serotonin Reuptake Inhibitors (SSRIs) and an Opioid on Ventilation","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2022-09-01","conditions":"Hypercapnia, Ventilatory Depression","enrollment":27},{"nctId":"NCT00958633","phase":"PHASE3","title":"Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.","status":"TERMINATED","sponsor":"University of British Columbia","startDate":"2010-11","conditions":"Bipolar I Disorder","enrollment":237},{"nctId":"NCT05002309","phase":"PHASE2","title":"Treatment Interrupts Depression Early","status":"RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2021-12-02","conditions":"Depression","enrollment":100},{"nctId":"NCT02752542","phase":"PHASE4","title":"Personalized Indications for CBT and Antidepressants in Treating Depression","status":"RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2016-10-31","conditions":"Major Depressive Disorder, Persistent Depressive Disorder","enrollment":80},{"nctId":"NCT04973930","phase":"PHASE3","title":"Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer","status":"SUSPENDED","sponsor":"New York State Psychiatric Institute","startDate":"2022-03-01","conditions":"Major Depressive Disorder, Breast Cancer, Venlafaxine","enrollment":20},{"nctId":"NCT02417064","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-10","conditions":"Treatment-resistant Depression","enrollment":346},{"nctId":"NCT03434041","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-05-25","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":252},{"nctId":"NCT02493868","phase":"PHASE3","title":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":719},{"nctId":"NCT02418585","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-07","conditions":"Treatment-resistant Depression","enrollment":236},{"nctId":"NCT02497287","phase":"PHASE3","title":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-30","conditions":"Treatment-resistant Depression","enrollment":802},{"nctId":"NCT02422186","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-20","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":139},{"nctId":"NCT03321526","phase":"PHASE2","title":"A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-12-12","conditions":"Depressive Disorder, Major","enrollment":107},{"nctId":"NCT04951609","phase":"PHASE1","title":"A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-09-02","conditions":"Depressive Disorder, Major","enrollment":31},{"nctId":"NCT03852160","phase":"PHASE3","title":"A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression","status":"WITHDRAWN","sponsor":"Janssen-Cilag International NV","startDate":"2019-12-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":""},{"nctId":"NCT06828887","phase":"PHASE2","title":"Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD","status":"RECRUITING","sponsor":"Vigonvita Life Sciences","startDate":"2025-04-03","conditions":"MDD","enrollment":400},{"nctId":"NCT03920410","phase":"NA","title":"Effect of Serotonergic Stimulation on the Gut-brain Axis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Örebro University, Sweden","startDate":"2019-04-24","conditions":"Healthy, Irritable Bowel Syndrome","enrollment":58},{"nctId":"NCT06796946","phase":"EARLY_PHASE1","title":"Deprescription of Antidepressants in Primary Care (DAPriCare)","status":"NOT_YET_RECRUITING","sponsor":"University of Huelva","startDate":"2025-04","conditions":"Deprescription, Antidepressants","enrollment":325},{"nctId":"NCT03128021","phase":"PHASE4","title":"Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)","status":"COMPLETED","sponsor":"Howard Aizenstein","startDate":"2017-05-24","conditions":"Major Depressive Disorder","enrollment":57},{"nctId":"NCT03854578","phase":"PHASE1","title":"A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-03-12","conditions":"Depressive Disorder, Major","enrollment":73},{"nctId":"NCT06412315","phase":"NA","title":"7T Amygdala and Citalopram Study","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-02-13","conditions":"Emotional Processing, Cognition, Mood Disorders","enrollment":50},{"nctId":"NCT01778686","phase":"NA","title":"Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors","status":"COMPLETED","sponsor":"Gitte Moos Knudsen","startDate":"2013-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT06740188","phase":"PHASE4","title":"Trazodone on NREM Sleep Stage Ⅲ in Depressed Insomniac Co-morbid Patients","status":"RECRUITING","sponsor":"Tongji University","startDate":"2025-01-01","conditions":"Depressed Insomniac Co-morbid Patients","enrollment":60},{"nctId":"NCT04598230","phase":"PHASE3","title":"Partners in Caring for Anxious Youth","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2021-02-09","conditions":"Anxiety, Separation, Anxiety, Generalized, Anxiety, Social","enrollment":468},{"nctId":"NCT00667121","phase":"","title":"Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2011-03-16","conditions":"Breast Cancer, Depression, Hot Flashes","enrollment":88},{"nctId":"NCT03108846","phase":"PHASE3","title":"Escitalopram for Agitation in Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"JHSPH Center for Clinical Trials","startDate":"2018-01-03","conditions":"Dementia","enrollment":187},{"nctId":"NCT06758167","phase":"NA","title":"RCT Study on the Therapeutic Effect of Escitalopram Loaded With XingpiJieyu Formula on Resting State EEG Energy Abnormalities in Severe Liver Depression and Spleen Deficiency Type MDD","status":"COMPLETED","sponsor":"Peking University Sixth Hospital","startDate":"2020-11-14","conditions":"Major Depression","enrollment":150},{"nctId":"NCT02473250","phase":"PHASE4","title":"Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2015-01","conditions":"Bipolar Disorder","enrollment":40},{"nctId":"NCT02431845","phase":"NA","title":"Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder","status":"RECRUITING","sponsor":"Severance Hospital","startDate":"2013-01-01","conditions":"Obsessive-Compulsive Disorder","enrollment":200},{"nctId":"NCT04336228","phase":"PHASE4","title":"The Role of Serotonin in Compulsive Behavior in Humans: Underlying Brain Mechanisms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2020-04-01","conditions":"Obsessive-Compulsive Disorder/High Compulsive Individuals, Healthy Individuals","enrollment":46},{"nctId":"NCT04301271","phase":"PHASE2","title":"Simvastatin add-on Treatment to Standard Antidepressant Therapy in Patients With Comorbid Obesity and Major Depression","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2020-08-13","conditions":"Depressive Disorder, Major, Obesity","enrollment":161},{"nctId":"NCT04446039","phase":"","title":"Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-07-04","conditions":"Major Depression","enrollment":370212},{"nctId":"NCT06696482","phase":"PHASE1, PHASE2","title":"Effort and Antidepressant Study Test","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2025-01","conditions":"Effort Based Decision Making, Prosocial Behavior, Apathy","enrollment":50},{"nctId":"NCT06680531","phase":"PHASE1","title":"A Clinical Study to Evaluate the Drug Interaction Between YZJ-1139 Tablets and Escitalopram Oxalate Tablets","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","startDate":"2024-08-31","conditions":"Insomnia, Central Nervous System","enrollment":24},{"nctId":"NCT06675851","phase":"PHASE4","title":"Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2022-12-01","conditions":"Major Depressive Disorder (MDD)","enrollment":120},{"nctId":"NCT03429075","phase":"PHASE2","title":"Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2019-01-07","conditions":"Depressive Disorder, Major","enrollment":59},{"nctId":"NCT04623099","phase":"PHASE4","title":"Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)","status":"RECRUITING","sponsor":"University of Cincinnati","startDate":"2021-03-08","conditions":"Anxiety","enrollment":132},{"nctId":"NCT04245436","phase":"PHASE4","title":"Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)","status":"RECRUITING","sponsor":"University of Cincinnati","startDate":"2020-01-01","conditions":"Anxiety, Depressive Symptoms","enrollment":60},{"nctId":"NCT04245748","phase":"PHASE4","title":"Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)","status":"RECRUITING","sponsor":"University of Cincinnati","startDate":"2020-03-01","conditions":"Anxious Depression, Depression","enrollment":84},{"nctId":"NCT04977232","phase":"NA","title":"Adjunctive Game Intervention for Anhedonia in MDD Patients","status":"COMPLETED","sponsor":"Central South University","startDate":"2021-09-09","conditions":"Depression","enrollment":50},{"nctId":"NCT06545474","phase":"NA","title":"Effects of rTMS Compared to SSRI as Early Treatment of Depression (Early-TMS)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2024-09-15","conditions":"Major Depressive Disorder","enrollment":106},{"nctId":"NCT00200902","phase":"PHASE4","title":"Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2005-08","conditions":"Depression","enrollment":88},{"nctId":"NCT05588102","phase":"NA","title":"Electronic Training of Elderly Depression With Cognitive Impairment","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2021-05-18","conditions":"Geriatric Depression, Cognitive Impairment","enrollment":128},{"nctId":"NCT05866575","phase":"NA","title":"Prediction of the Therapeutic Response in Depression Based on Neuro-computational Modeling Assessment of Motivation","status":"RECRUITING","sponsor":"Centre Hospitalier St Anne","startDate":"2023-09-12","conditions":"Major Depressive Disorder","enrollment":136},{"nctId":"NCT05599126","phase":"PHASE4","title":"A Study of Mianserin in Combination With SSRIs in Depression With Sleep Problems","status":"RECRUITING","sponsor":"Zhenghui YI","startDate":"2024-07-01","conditions":"Depression","enrollment":300}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"URINARY TRACT INFECTION"},{"count":2,"reaction":"DEPRESSION"},{"count":2,"reaction":"DRUG INEFFECTIVE"},{"count":2,"reaction":"DYSPNOEA"},{"count":2,"reaction":"HYPOXIA"},{"count":2,"reaction":"MOVEMENT DISORDER"},{"count":2,"reaction":"PARAESTHESIA"},{"count":2,"reaction":"SEPSIS"},{"count":1,"reaction":"ABASIA"},{"count":1,"reaction":"ABDOMINAL DISCOMFORT"}],"_approvalHistory":[],"publicationCount":42,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"citalopram (celexa)","genericName":"citalopram (celexa)","companyName":"Sunnybrook Health Sciences Centre","companyId":"sunnybrook-health-sciences-centre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Citalopram selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain. Used for Major depressive disorder, Panic disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}